Mirae Asset Global Investments
MLYS icon

Mirae Asset Global Investments’s Mineralys Therapeutics MLYS Stock Holding History

Mirae Asset Global Investments’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.6K Sell
3,690
-438
-11% -$12K ﹤0.01% 1238
2026
Q1 		$112K Buy
4,128
+282
+7% +$8.27K ﹤0.01% 1162
2025
Q4 		$140K Buy
3,846
+1,283
+50% +$51.5K ﹤0.01% 1202
2025
Q3 		$97.2K Buy
2,563
+45
+2% +$973 ﹤0.01% 1216
2025
Q2 		$34.1K Buy
2,518
+850
+51% +$12.3K ﹤0.01% 1311
2025
Q1 		$24.5K Buy
1,668
+10
+0.6% +$115 ﹤0.01% 1368
2024
Q4 		$21.3K Sell
1,658
-141
-8% -$1.84K ﹤0.01% 1418
2024
Q3 		$21.4K Buy
1,799
+317
+21% +$3.84K ﹤0.01% 1425
2024
Q2 		$17K Buy
+1,482
New +$18.7K ﹤0.01% 1405

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Mirae Asset Global Investments's MLYS Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Mineralys Therapeutics (MLYS) stake by 11% in Q2 2026, selling an estimated $12K and leaving 3,690 shares worth $99.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1238.

Mirae Asset Global Investments first reported a position in MLYS in Q2 2024 and has held it in 9 quarters since. The position peaked at $140K in Q4 2025. 58 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Mirae Asset Global Investments held 3,690 shares of Mineralys Therapeutics worth $99.6K as of Q2 2026.
  • Mirae Asset Global Investments sold 438 Mineralys Therapeutics shares in Q2 2026, an estimated $12K.
  • Mineralys Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1238 holding.
  • Mirae Asset Global Investments first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global Investments's Mineralys Therapeutics position peaked at $140K in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.